Literature DB >> 3136023

The human intermediate-affinity interleukin 2 receptor consists of two distinct, partially homologous glycoproteins.

T Herrmann1, T Diamantstein.   

Abstract

In this report we demonstrate that the human intermediate-affinity-type interleukin (IL) 2 receptor (IL 2R) consists of two distinct glycoproteins designated H1 and H2, whereas the high-affinity IL 2R consists of three chains, H1, H2 and the light chain (L), the Tac antigen. They are neither linked by disulfide bridges to each other nor to the L chain. Similar to the L chain, H1 and H2 apparently carry intramolecular disulfide bonds. From affinity-labeled IL 2 intermediate-affinity receptor complexes, we deduced an apparent mol. mass of 70 kDa for H1 and of 75 kDa for H2 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and of 55 kDa for H1 and of 85 kDa for H2 in SDS-PAGE/urea. As demonstrated by limiting proteolysis, both glycoproteins display high homologies or even identity proximal to the IL 2-binding sites. The areas which are responsible for the striking differences between H1 and H2 in SDS-PAGE/urea are located distally to the IL2-binding site and, in contrast to the L chain, are protected from the action of exogenous proteases by the plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136023     DOI: 10.1002/eji.1830180713

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Demonstration of two distinct forms of released low affinity-type rat IL-2 receptors.

Authors:  T Herrmann; O Josimovic-Alasevic; A Mouzaki; T Diamantstein
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

2.  The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.

Authors:  H D Volk; O Josimovic-Alasevic; M Gross; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Authors:  S D Voss; J A Hank; C A Nobis; P Fisch; J A Sosman; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor.

Authors:  K Sauvé; M Nachman; C Spence; P Bailon; E Campbell; W H Tsien; J A Kondas; J Hakimi; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

5.  Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

Authors:  M Tsudo; F Kitamura; M Miyasaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Interleukin-4 regulates the interleukin-2 receptors on human peripheral blood B lymphocytes.

Authors:  K Tomizawa; A Ishizaka; K Kojima; M Nakanishi; Y Sakiyama; S Matsumoto
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling.

Authors:  N Arima; M Kamio; K Imada; T Hori; T Hattori; M Tsudo; M Okuma; T Uchiyama
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.